Foundation Medicine: Cindy Perettie
Foundation Medicine, a Roche subsidiary, announced Cindy Perettie would be transitioning to Roche Diagnostics to lead the molecular lab solutions business, effective April 6. Perettie has been the CEO of Foundation Medicine since 2019 and previously served as senior VP with product strategy responsibility for the global oncology portfolio at Roche and Genentech. She also led global portfolio management for IVAX Pharmaceuticals and was the president of global development innovations at the Sarah Cannon Research Insitute in Nashville. In addition, she was previously the director of global program management at Élan Corporation in the United Kingdom.
Brian Alexander, Foundation's chief medical officer and senior VP, will be the interim CEO for the company.
Sophia Genetics: Kathy Hibbs
Sophia Genetics has named Kathy Hibbs to its board of directors and to its audit committee. Hibbs, the chief legal and regulatory officer at 23andMe, has been chosen for several boards in recent years, including those of Decipher Biosciences and Cadex Genomics. Prior to joining 23andMe, Hibbs served as senior VP and general counsel at Genomic Health.
Circulogene: Stephen Unger
Circulogene has appointed Stephen Unger as its CFO. Unger most recently served as a managing director of equity research at Needham & Company. He has also served as CFO of Quotient, which completed a successful initial public offering in 2014.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.